← All trials
NCT00795769
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 8, 2008
- Primary completion
- Jun 9, 2009
- Completion date
- Jun 10, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 49
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
Drugs studied
Indications studied
- Breast Neoplasms
- Burkitt Lymphoma
- Hodgkin Disease
- Leukemia, Hairy Cell
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neuroblastoma
- Ovarian Neoplasms
- Sezary Syndrome
- Testicular Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Neutrophilic, Chronic
- Leukemia, Myeloid, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Myelomonocytic, Chronic
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.